Wegovy (semaglutide) is approved for weight management in people with obesity, and adults with overweight who have a weight-related comorbidity such as high cholesterol or type 2 diabetes
Whilst synthetic GLP-1 receptor agonists such as semaglutide have gained prominence for diabetes and weight management, many people seek evidence-based strategies to enhance their body's own GLP-1 production
However, these medications do not directly target thyroid function or autoimmune processes, which is an important distinction when considering their potential role in Hashimoto's disease management
The key is managing expectations: these are supportive tools, not pharmaceutical replacements
Excess skin removal may be covered when medically necessary, especially if rashes, infections, or functional problems are documented
Wegovy (semaglutide) is an FDA-approved prescription medication used for chronic weight management in adults with obesity or excess weight